10x Genomics Management
Management criteria checks 3/4
10x Genomics' CEO is Serge Saxonov, appointed in Jul 2012, has a tenure of 12.33 years. total yearly compensation is $8.29M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 3.32% of the company’s shares, worth $57.59M. The average tenure of the management team and the board of directors is 2.8 years and 5.4 years respectively.
Key information
Serge Saxonov
Chief executive officer
US$8.3m
Total compensation
| CEO salary percentage | 6.6% |
| CEO tenure | 12.3yrs |
| CEO ownership | 3.3% |
| Management average tenure | 2.8yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Nov 01
10x Genomics: Deciphering The Preliminary Q3 Earnings
Oct 12The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%
Oct 1110x Genomics Is Still A Long Way From Profitability
Oct 03We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$183m |
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$100m |
| Jun 30 2019 | n/a | n/a | -US$105m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$1m | US$366k | -US$112m |
Compensation vs Market: Serge's total compensation ($USD8.29M) is above average for companies of similar size in the US market ($USD5.43M).
Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.
CEO
Serge Saxonov (47 yo)
12.3yrs
Tenure
US$8,286,050
Compensation
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.32% $ 57.6m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 46.3m | |
| Chief Legal Officer | 7.3yrs | US$3.88m | 0.12% $ 2.0m | |
| CFO, Treasurer | less than a year | no data | no data | |
| Chief of Global Operations | less than a year | no data | no data | |
| Founding Scientist & CTO | 2.8yrs | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| Manager of Investor Relations & Strategic Finance | no data | no data | no data | |
| Chief People Officer | 3.8yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Associate Director of Product Management | no data | no data | no data |
2.8yrs
Average Tenure
48.5yo
Average Age
Experienced Management: TXG's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.32% $ 57.6m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 46.3m | |
| Independent Director | 4.7yrs | US$338.71k | 0.0038% $ 66.0k | |
| Independent Chairman | 11.3yrs | US$403.59k | 2.02% $ 34.9m | |
| Independent Director | 5.3yrs | US$336.39k | 0.0038% $ 66.0k | |
| Director | less than a year | no data | no data | |
| Independent Director | 5.6yrs | US$346.39k | 0.029% $ 507.2k | |
| Director | less than a year | no data | no data |
5.4yrs
Average Tenure
52yo
Average Age
Experienced Board: TXG's board of directors are considered experienced (5.4 years average tenure).